|
gptkbp:instanceOf
|
gptkb:biotechnology
|
|
gptkbp:acquiredBy
|
gptkb:Epizyme
gptkb:Clementia_Pharmaceuticals
|
|
gptkbp:CEO
|
gptkb:David_Loew
|
|
gptkbp:focusArea
|
specialty care
innovative medicines
|
|
gptkbp:foundedIn
|
1929
|
|
gptkbp:founder
|
gptkb:Henri_Beaufour
|
|
gptkbp:hasResearchCenter
|
gptkb:Cambridge,_Massachusetts,_USA
gptkb:Les_Ulis,_France
gptkb:Oxford,_UK
|
|
gptkbp:headquartersLocation
|
gptkb:Paris,_France
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Ipsen
|
|
gptkbp:industry
|
pharmaceuticals
|
|
gptkbp:listedOn
|
gptkb:CAC_Mid_60
|
|
gptkbp:market
|
global
|
|
gptkbp:notableProduct
|
gptkb:Cabometyx
gptkb:Decapeptyl
gptkb:Somatuline
gptkb:Dysport
|
|
gptkbp:numberOfEmployees
|
over 5,700
|
|
gptkbp:operatesIn
|
over 115 countries
|
|
gptkbp:parentCompany
|
gptkb:Beaufour_family
|
|
gptkbp:publiclyTraded
|
yes
|
|
gptkbp:revenue
|
€3.0 billion (2023)
|
|
gptkbp:specializesIn
|
neuroscience
oncology
rare diseases
|
|
gptkbp:stockExchange
|
gptkb:Euronext_Paris
|
|
gptkbp:stockSymbol
|
gptkb:IPN
|
|
gptkbp:website
|
https://www.ipsen.com/
|
|
gptkbp:bfsParent
|
gptkb:cabozantinib
gptkb:PhRMA
|
|
gptkbp:bfsLayer
|
6
|